Stock A023910 DAIHAN PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Daihan Pharmaceutical Co.,Ltd.

Equities

A023910

KR7023910003

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
28,350 KRW -0.70% Intraday chart for Daihan Pharmaceutical Co.,Ltd. -1.90% +2.16%
2023 Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index CI
2023 Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company shows low valuation levels, with an enterprise value at 782.52 times its sales.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DAIHAN PHARMACEUTICAL CO.,LTD. Stock Daihan Pharmaceutical Co.,Ltd.
+2.16% 121M -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.79% 43.03B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+23.86% 22.7B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+16.48% 15.07B -
CIPLA LIMITED Stock Cipla Limited
+24.19% 14.77B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.51% 13.05B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-14.19% 6.58B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.42% 5.5B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A023910 Stock
  4. Ratings Daihan Pharmaceutical Co.,Ltd.